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Abstract
Importance—Apart from hysterectomy, there is no consensus recommendation for reducing 
endometrial cancer risk for women with a mismatch repair (MMR) gene mutation (Lynch 
syndrome).
Objective—To investigate the association between hormonal factors and endometrial cancer risk 
in Lynch syndrome.
Design, Setting, and Participants—A retrospective cohort study including 1,128 women 
with a MMR gene mutation identified from the Colon Cancer Family Registry was conducted. 
Data were analyzed using a weighted cohort approach. Participants were recruited between 1997 
and 2012, from centers across the United States, Australia, Canada, and New Zealand.
Exposures—Age at menarche, first and last live birth, and menopause, number of live births, 
hormonal contraceptive use, and postmenopausal hormone use.
Main Outcome and Measures—Self-reported diagnosis of endometrial cancer.
Results—Endometrial cancer was diagnosed in 133 women (incidence per 100 person-years, 
0.29; 95% confidence interval [CI], 0.24 to 0.34). A lower risk of endometrial cancer was 
associated with later age at menarche (hazard ratio [HR] per year, 0.85 [95%CI, 0.73 to 0.99]; P=.
04), parity (parous vs nulliparous: HR, 0.21 [95%CI, 0.10 to 0.42]; P<.001), and hormonal 
contraceptive use (≥1 year vs <1 year: HR, 0.39 [95%CI, 0.23 to 0.64]; P<.001). There was no 
statistically significant association between endometrial cancer and age at first and last live birth, 
age at menopause, and postmenopausal hormone use.
Conclusions and Relevance—For women with a MMR gene mutation, some endogenous and 
exogenous hormonal factors were associated with a lower risk of endometrial cancer. These 
directions and strengths of associations were similar to those for the general population. If 
replicated, these findings suggest that women with a MMR gene mutation may be counseled like 
the general population in regard to hormonal influences on endometrial cancer risk.
Keywords
mismatch repair; endometrial cancer; reproductive factors; hormonal factors; pregnancy; 
contraceptives; Lynch syndrome
Introduction
Endometrial cancer is the most common type of gynecologic cancer in developed 
countries.1, 2 Two to five percent of all endometrial cancer cases are associated with a 
hereditary susceptibility to cancer, mainly Lynch syndrome.3 Lynch syndrome is an 
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autosomal dominant disorder caused by a germline mutation in one of the DNA mismatch 
repair (MMR) genes MLH1 (RefSeq NM_000249), MSH2 (RefSeq NM_000251), MSH6 
(RefSeq NM_000179), PMS2 (RefSeq NM_000535), and EPCAM (RefSeq NM_000535).4 
Though estimates vary, the incidence of Lynch syndrome may be as high as 1 in 370 in the 
general population in the USA.5 Depending on the mutated gene, cumulative risk of 
developing endometrial cancer by age 70 years for women is thought to be between 15% 
and 30%.678 Apart from hysterectomy, there is no consensus recommendation for reducing 
endometrial cancer risk for women with a MMR gene mutation.9,10
Studies in the general population have shown factors that increase the bioavailability of 
estrogen unopposed by progesterone, including obesity,11 early age at menarche, late age at 
menopause, nulliparity, and use of estrogen-only menopausal hormone therapy increase 
endometrial cancer risk.12, 13 On the other hand, hormonal contraceptive use, higher number 
of pregnancies, and later age at first and last live birth have been shown to reduce 
endometrial cancer risk.12, 13
For Lynch syndrome, the association between female hormonal factors and endometrial 
cancer risk is not clear. Results from a multicenter randomized trial that studied the 
influence of oral contraceptive and medroxyprogesterone acetate on endometrial 
proliferation in 51 women with Lynch syndrome suggested that, similar to the general 
population, short-term exposure to exogenous progesterone reduced endometrial epithelial 
proliferation in this group of women.14
In the present study, we estimated the associations between endometrial cancer risk and 




This was a retrospective cohort study that included women with a heterozygous germline 
pathogenic mutation in a MMR gene, who had been recruited by the Colon Cancer Family 
Registry. Study design and recruitment strategy have been published in detail and are 
available at http://coloncfr.org.15 Probands were those who had either recently received a 
diagnosis of colorectal cancer that was reported to state or regional population cancer 
registries in the USA (Washington, Minnesota, California, Arizona, Colorado, New 
Hampshire, North Carolina, and Hawaii), Australia (Victoria), and Canada (Ontario); or they 
were persons from multiple-case families referred to family-cancer clinics in the USA 
(Mayo Clinic, Rochester, Minnesota and Cleveland Clinic, Ohio), Canada (Ontario), 
Australia (Melbourne, Adelaide, Perth, Brisbane, Sydney), and New Zealand (Auckland). 
Individuals were recruited and interviewed between 1997 and 2012 and were asked for 
permission to contact their relatives and seek their enrollment in the Colon Cancer Family 
Registry. For population-based families, first-degree relatives of probands were recruited at 
all centers and, at some centers, recruitment was extended to more distant relatives. For 
clinic-based families, recruitment was attempted up to second-degree relatives of affected 
individuals (detail in Newcomb et al.).15 Participants were followed up approximately every 
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5 years after baseline to update this information. For this study, 2011 was the last date of 
outcome assessment and censoring. Informed consent was obtained from all study 
participants and the study protocol was approved at each involved center by their 
institutional research ethics review boards.
Data Collection
At recruitment (baseline), information on demographics, personal characteristics, personal 
and family history of cancer, and history of cancer screening and any surgery including 
gynecologic surgery, was obtained using standardized questionnaire via personal interviews, 
telephone interviews, or mailed questionnaires from all participants. The questionnaires used 
at each Colon Cancer Family Registry center are available at http://coloncfr.org/
questionaires. When possible, reported cancer diagnoses and age at diagnosis were 
confirmed using pathology review and reports, medical records, cancer registry reports, 
and/or death certificates. We attempted to obtain blood samples from all participants and 
tumor tissue samples from all participants affected with colorectal cancer.
MMR gene mutation testing
Testing for germline mutations in MLH1, MSH2, MSH6, and PMS2 was performed for all 
population-based probands who had a colorectal tumor displaying evidence of impaired 
MMR function as evidenced by tumor microsatellite instability (MSI) and/or by lack of 
MMR-protein expression in immunohistochemical (IHC) analysis. Testing was undertaken 
for the youngest-onset colorectal cancer participant from each clinic-based family regardless 
of MSI or MMR-protein expression status. Mutation testing for the MLH1, MSH2, and 
MSH6 genes was performed by Sanger sequencing or denaturing high performance liquid 
chromatography (dHPLC), followed by confirmatory DNA sequencing. Large duplication 
and deletion mutations were detected by Multiplex Ligation Dependent Probe Amplification 
(MLPA) according to the manufacturer’s instructions (MRC Holland, Amsterdam, The 
Netherlands).15–17 PMS2 mutation testing involved a modified protocol from Senter et al. 8 
where exons 1–5, 9 and 11–15 were amplified in three long-range PCRs, followed by nested 
exon specific PCR/sequencing, with the remaining exons (6, 7, 8 and 10) being amplified 
and sequenced direct from genomic DNA. Large-scale deletions in PMS2 were detected 
using the P008-A1 MLPA kit (MRC Holland, Amsterdam, The Netherlands). Relatives of 
probands with a pathogenic MMR germline mutation18 who provided a blood sample 
underwent testing for the specific mutation identified in the proband.
Statistical analysis
Cox proportional regression models with age as the time scale were used to estimate any 
association between female hormonal factors (see Box 1 for definitions) and endometrial 
cancer risk. Time at risk started at birth and ended at age of endometrial cancer diagnosis, 
any other cancer diagnosis, hysterectomy, or interview, whichever occurred first. We 
censored at age of diagnosis of any primary cancer because resultant treatment and 
surveillance might have altered endometrial cancer risk. In addition, carriers might have 
changed their behavior following the diagnosis of cancer.
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Definitions of outcome and exposures
All the definitions were pre-defined prior to analysis of the data.
Primary Outcome: Self-reported diagnosis of endometrial cancer.
Primary Exposures: Self-reported endogenous and exogenous hormonal factors.
Number of live births was defined as the number of pregnancies that resulted in a live 
birth. Given that the questionnaires did not elicit age at each birth, we defined number of 
live births based on self-reported number of live births, age at first and last live birth and 
censored age. Women with age at first live birth younger than censored age were 
categorized as parous and women with age at first live birth older than censored age were 
categorized as nulliparous.
Ever use of hormonal contraceptive was defined as use of oral contraceptives or other 
hormonal contraceptives (implants or injections) for at least one year. Based on the 
reported age at first use and number of years of hormonal contraception use, and 
assuming that the use had been continuous, age at last use of hormonal contraception was 
calculated. When this age was older than censored age, years of hormonal contraception 
use was calculated based on censored age and age at first use.
Age at menopause was defined as age when menstrual cycles stopped for at least 12 
months. Natural menopause was defined as self-reported cessation of menstrual cycles 
for at least 12 months. Induced menopause was defined as cessation of menstrual cycles 
for at least 12 months due to gynecologic surgery, radiation or chemotherapy, or other 
reasons.
Women with unknown menopausal status were assumed to have had natural menopause 
if they were 60 years or older at the time of censoring. For this group of women, age at 
menopause was considered at 56, which was the oldest age at natural menopause reported 
in this cohort. Ever use of postmenopausal hormones (PMH) was use of a pill or patch 
for at least one year. Estrogen-only use was defined as having used estrogen-only pills or 
patches for at least 1 year. Estrogen and progesterone combination was defined as having 
used progesterone along with estrogen for at least one year. Based on the reported age at 
first use and number of years of PMH use and assuming that the use had been 
continuous, age at last use of PMH was calculated. When this age was older than 
censored age, years of PMH use was calculated based on censored age and age at first 
use.
Since a proportion of women in this study was ascertained from multiple-case cancer-
families and cases were tested preferentially for MMR gene mutations, selection of women 
was not random with respect to disease status. To take this non-random ascertainment of 
cases into account, we applied probability weights to women based on the approach 
described by Antoniou et al.19 Age-specific incidences of endometrial cancer for women 
were calculated by multiplying the country- and age-specific population incidences by the 
hazard ratio (HR) of endometrial cancer for women with a specific MMR gene mutation. 
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Average age-specific population incidences in 1998–2002 for each country (Australia, 
Canada, and USA) were obtained from Cancer Incidence in Five Continents.20 These age-
specific incidences of endometrial cancer for women with MMR gene mutations were used 
to calculate statistical weights for women with and without endometrial cancer in each age-
stratum.
The proportional hazards (PH) assumption was tested using the Schoenfeld and scaled 
Schoenfeld residuals.21 Bivariable and multivariable models were fit separately for each 
hormonal factor. The variables that we considered as potential confounders are listed in 
Table 1. The variables that did not meet the PH assumption were stratified for in the model. 
Tests for interactions were assessed by a change in the log-likelihood ratio after the addition 
of a cross-product term between the exposure and potential effect modifiers identified a 
priori. The overall model fit was assessed using Cox-Snell residuals as the time variable and 
plotting them against the Nelson-Aalen cumulative hazard function.22
For multivariable models, missing data were handled using both complete case analysis and 
multiple imputation. Numbers of missing values for all the variables are reported in Table 1a 
and 1b. Assuming that missing was at random, missing data were imputed using chained 
equations.23, 24 Variables included in the imputation model were outcome status, age at the 
time of endometrial cancer diagnosis or censored age, year of birth, country, mutated gene, 
ascertainment method (clinic vs. population), and whether the carrier was a proband. Fifty 
imputed datasets were created.
When age variables (i.e. age at menarche, age at first and last live birth, and age at 
menopause) were the primary exposures, we analyzed them as categorical variable as well 
as continuous variable in two different models. We used the median values as the cut-off 
points to categorize these variables.
We conducted the following additional analyses: i) analyses restricted to women who were 
diagnosed with endometrial cancer or censored within 5 years before interview to reduce 
survival bias; ii) analyses restricted to women with verified endometrial cancer diagnosis 
and unaffected women; iii) analyses for women ascertained through clinic-based and 
population-based resources, and for the four mutated MMR genes; and iv) analyses in which 
we did not censor women at age of first diagnosis of any other cancer.
To account for potential correlation of risk between family members, the Huber-White 
robust variance correction was used by clustering on family membership.25, 26 All statistical 
tests were two-sided and P value <.05 was considered statistically significant. All statistical 
analyses were performed using Stata 13.0.27
Results
We identified 1,133 women with a MMR gene mutation from the Colon Cancer Family 
Registry. Of these, 5 (0.4%) who were younger than age 18 years were excluded. The final 
sample included 1,128 women from 548 independent families, contributing a total of 45,831 
person-years. Of these women, 424 carried a mutation in MLH1, 532 in MSH2, 117 in 
MSH6, and 55 in PMS2.
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Time at risk ended at age at: endometrial cancer diagnosis for 133 women; any other cancer 
diagnosis for 417; hysterectomy for 229; and interview for 349. In this cohort, endometrial 
cancer incidence rate was 0.29 per 100 person-years (95% confidence interval [CI], 0.24 to 
0.34) with a mean age of diagnosis of 45.9 (standard deviation 8.2). We were able to 
confirm endometrial cancer diagnosis for 101 (76%) women by pathology review or report, 
cancer registries, or hospital record. Characteristics of women included in this study are 
summarized in Table 1a and Table 1b.
The results of Cox regression models and adjusted variables in each model are summarized 
in Table 2 and Table 3. There was a statistically significant association between later age at 
menarche and a lower risk of endometrial cancer (endometrial cancer incidence rate per 100 
person-years for women with age at menarche ≥ 13 vs. <13 years: 0.27 vs. 0.31; rate 
difference, −0.04 [95%CI, −0.15 to 0.05]; HR per year, 0.85 [95%CI, 0.73 to 0.99]; P=.04). 
There was also an inverse association between endometrial cancer risk and parity (incidence 
rate per 100 person-years for parous vs. nulliparous women: 0.26 vs. 0.43; rate difference, 
−0.18 [95%CI, −0.32 to −0.04]; HR, 0.21 [95%CI, 0.10 to 0.42]; P<.001). We did not 
observe statistically significant association between endometrial cancer risk and age at first 
live birth (P=.46), age at last live birth (P=.62), or age at menopause (P=.96) (Table 2).
Ever use of hormonal contraceptives was associated with a lower endometrial cancer risk 
compared with never use (incidence rate per 100 person-years for ≥1 year vs. <1 year use: 
0.22 vs. 0.45; rate difference, −0.23 [95%CI, −0.36 to −0.11]; HR, 0.39 [95%CI, 0.23 to 
0.64]; P<.001). There was no statistically significant association between PMH use and 
endometrial cancer risk (P=.57), even after stratifying the type of PMH (estrogen-only or 
estrogen and progestin combination) (Table 3). Due to small number of women (1%) who 
reported use of anti-estrogen drugs (including Tamoxifen and Raloxifene), we were unable 
to investigate associations between these drugs and endometrial cancer risk in this study.
There was no statistically significant evidence that cigarette smoking status, BMI at age 20, 
country, specific MMR gene, and ascertainment method modified any of observed 
associations (eTable 1).
In an analysis restricted to women who were diagnosed with endometrial cancer or censored 
within 5 years before interview, we found the results similar to the main analysis (eTable 2). 
In sensitivity analyses restricted to women with verified endometrial cancer diagnosis and 
unaffected women, results were similar to the main analysis. Although the statistical power 
was poor, the patterns of associations remained the same in analyses stratified by 
ascertainment (clinic- and population-based) and by mutated gene (MLH1, MLH2, MSH6, 
and PMS2) (eTables 3 – 6). We also observed similar results in analyses that did not censor 
women at their age of first diagnosis of any other cancer (eTable 7). When we additionally 
adjusted for recent BMI in the multiple imputation analyses, the results were similar to the 
main analyses (eTable 8).
There was no evidence that main exposure variables violated the PH assumption in any of 
the final models. The directions and strengths of associations were similar in both un-
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weighted and weighted cohort analyses although the standard errors of the estimates were 
increased in weighted analyses.
Discussion
In this study, an inverse association was observed between the risk of endometrial cancer for 
women with a MMR gene mutation and late age of menarche, increased parity, and use of 
hormonal contraceptives. The directions of the observed associations are similar to those 
that have been reported for the general population suggesting a possible protective effect of 
these factors.12, 13, 28–32 Unlike observations for women from the general 
population,12, 13, 33, 34 there was no statistically significant association between age at 
menopause and endometrial cancer risk in Lynch syndrome. About 80% of women in our 
cohort were pre-menopausal and age at menopause was unknown for about 22% of post-
menopausal women. Similarly, we did not observe statistically significant association 
between endometrial cancer risk and age at first and last live birth in Lynch syndrome, 
which is in line with some13, 35 but not all studies35, 36 conducted in the general 
population.37 The lack of an observed association between endometrial cancer risk and 
PMH use in this study could be attributed to lack of statistical power (only 2.8% reported 
use of estrogen-only and 4.3% reported use of combined estrogen and progesterone for at 
least one year). Additional unmeasured confounding or information bias could also account 
for this finding.
Given that Lynch syndrome-associated cancers typically exhibit high level of MSI and/or 
loss of MMR protein expression by IHC, these tests have been widely used as screening 
methods for likely MMR germline mutation carriers. However, neither of these tests is 
diagnostic and germline testing is required to confirm mutation carrier status.38 For 
example, MSI is seen in approximately 30% of sporadic endometrial cancers.39 Amankwah 
et al.40 investigated the association between hormonal factors and the risk of microsatellite 
stable (MSS; n=103) and MSI (n=258) endometrial cancer. Similar to our results, 
Amankwah et al. reported a reduced risk of MSI endometrial cancer for parous women 
compared with nulliparous women (odds ratio [OR], 0.53 [95%CI, 0.28 to 1.02]), and for 
women who used oral contraceptives for at least 5 years compared with those who used less 
than 6 months (OR, 0.43 [95%CI, 0.23 to 0.77]). There was an increasing risk reduction of 
endometrial cancer associated with a longer duration of oral contraceptives use, and a 
stronger inverse association for women with a MSI tumor compared with women with a 
MSS tumor.
An inverse association between endometrial proliferation and hormonal contraceptives in 
Lynch syndrome was also reported in a multicenter randomized trial.14 In that study, 51 
women with a known MMR gene mutation or a personal history of Lynch syndrome-
associated cancer who met Amsterdam criteria were randomly assigned to receive either oral 
contraceptive pills or medroxyprogesterone acetate for 3 months and assessed for 
endometrial proliferation before and after treatment. A significant decrease in endometrial 
epithelial proliferation was observed post treatment in both groups compared with before 
treatment, suggesting that hormonal contraceptives may be useful chemopreventive agents 
in these high-risk women. Our results provide further evidence supporting the hypothesis 
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that long-term exposure to hormonal contraceptives may significantly reduce the risk of 
endometrial cancer in Lynch syndrome.
To our best knowledge, this is the largest study to date investigating the association between 
endometrial cancer risk and hormonal factors in Lynch syndrome. To overcome bias in 
retrospective studies where subjects are selected on the basis of disease, we used a weighted 
cohort approach,19 which has been successfully used in studies of modifiers of cancer risk 
associated with rare genetic mutations.10, 41, 42 Data for this study came from the Colon 
Cancer Family Registry, which used standardized and uniform materials for collection of 
epidemiology, family, and cancer data as well as genetic testing.
Our study had several limitations. There might be errors in the measurement of exposure 
variables and other adjusted variables, as the measurements came from self-reported 
questionnaires. For individuals who were diagnosed with endometrial cancer or censored at 
an age younger than their age at interview, years of hormonal contraception and PMH use 
were calculated based on self-reported age at first use and number of years of hormone use, 
assuming that use had been continuous. This method may have overestimated the years of 
hormone use in some carriers. However, this potential misclassification would more 
probably bias the results towards the null and would not account for the observed inverse 
association between endometrial cancer risk and years of hormonal contraceptive. Recall of 
all exposure may have been affected by disease status in our cohort because women were 
diagnosed with endometrial cancer before interview. To determine whether survival bias 
influenced the observed associations, we conducted a sensitivity analysis restricted to 
women who were diagnosed with endometrial cancer or censored within 5 years before 
interview; we observed findings similar to the main analysis. Another potential limitation of 
our study is the lack of a valid measure of recent BMI for 52% of all women. BMI is a 
strong and consistent risk factor for endometrial cancer and has been reported to be a 
confounder for the association between endometrial cancer risk and hormonal factors for the 
general population.11, 43 However, there is some evidence that recent BMI is not associated 
with endometrial cancer in Lynch syndrome.44–47 In our complete case analysis, BMI at age 
20 was available and did not confound or modify the association between endometrial 
cancer risk and any of hormonal factors. Further, imputed recent BMI did not confound any 
of those associations.
Conclusions
For women with a MMR gene mutation, some endogenous and exogenous hormonal factors 
were associated with a lower risk of endometrial cancer. These directions and strengths of 
associations were similar to those for the general population. If replicated, these findings 
suggest that women with a MMR gene mutation may be counseled like the general 
population in regard to hormonal influences on endometrial cancer risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1a
Characteristics of women with a germline mutation in a DNA mismatch repair gene
No endometrial cancer
N = 995 (88.2%)
Endometrial cancer
N = 133 (11.8%)
Total
N = 1,128
Study Centers, n (%)
 Australia or New Zealand 557 (56.0) 52 (39.1) 609 (54.0)
 USA 290 (29.2) 50 (37.6) 340 (30.1)
 Canada 148 (14.9) 31 (23.3) 179 (15.9)
Race
 Caucasian 923 (92.8) 128 (96.1) 1,051 (93.2)
 Other 51 (5.1) 4 (3.0) 55 (4.9)
 Missing 21 (2.1) 1 (0.8) 22 (1.9)
Ascertainment method
 Clinic 742 (74.6) 102 (76.7) 844 (74.8)
 Population 253 (25.4) 31 (23.3) 284 (25.2)
Age (year),1
 mean (SD) 39.9 (11.4) 45.9 (8.2) 40.6 (11.3)
 median [range] 40 [18 – 86] 46 [25 – 68] 40 [18 – 86]
Year of Birth, n (%)
 1914–1943 215 (21.6) 47 (35.3) 262 (23.2)
 1944–1954 237 (23.8) 53 (39.9) 290 (25.7)
 1955–1965 278 (27.9) 26 (19.6) 304 (27.0)
 1966–1990 265 (26.6) 7 (5.3) 272 (24.1)
Education level, n (%)
 Primary or less 19 (1.9) 2 (1.5) 21 (1.9)
 Some high school 201 (20.2) 31 (23.3) 232 (20.6)
 Completed high school/ some tertiary study 355 (35.7) 45 (33.8) 400 (35.5)
 Vocational/technical school 171 (17.2) 15 (11.3) 186 (16.5)
 University degree 232 (23.3) 39 (29.3) 271 (24.0)
 Missing 17 (1.7) 1 (0.8) 18 (1.6)
Mismatch repair gene mutated, n (%)
 MLH1 392 (39.4) 32 (24.1) 425 (37.6)
 MSH2 457 (45.9) 75 (56.4) 532 (47.2)
 MSH6 94 (9.5) 23 (17.3) 117 (10.4)
 PMS2 52 (5.2) 3 (2.3) 55 (4.9)
Family history of colorectal and/or endometrial cancer
 No family history 178 (17.9) 21 (15.8) 199 (17.6)
 First-degree relative 137 (13.8) 28 (21.1) 165 (14.6)
 Second-degree relative 79 (7.9) 7 (21.1) 86 (7.6)
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No endometrial cancer
N = 995 (88.2%)
Endometrial cancer
N = 133 (11.8%)
Total
N = 1,128
 First- and second- degree relative 601 (60.4) 77 (57.9) 678 (60.1)
Body mass index at age 20,2 n (%)
 Normal 672 (67.5) 97 (72.9) 769 (68.2)
 Overweight 95 (9.6) 15 (11.3) 110 (9.8)
 Obese 36 (3.6) 4 (3.0) 40 (3.6)
 Underweight 136 (13.7) 10 (7.5) 146 (12.9)
 Missing 56 (5.6) 7 (5.3) 63 (5.6)
Body mass index 2 years before diagnosed/ censored age,2* n (%)
 Normal 294 (29.6) 10 (7.5) 304 (27.0)
 Overweight 129 (13.0) 2 (1.5) 131 (11.6)
 Obese 78 (7.8) 9 (6.8) 87 (7.7)
 Underweight 22 (2.2) 2 (1.5) 24 (2.1)
 Missing 472 (47.4) 110 (82.7) 582 (51.6)
Diabetes, n (%)
 No 965 (967.0) 128 (96.2) 1,093 (96.9)
 Yes 15 (1.5) 1 (0.8) 16 (1.4)
 Missing 15 (1.5) 4 (3.0) 19 (1.7)
Aspirin and/or ibuprofen intake,3 n (%)
 <1 month 799 (80.3) 97 (72.9) 896 (79.4)
 ≥1 month 127 (12.8) 16 (12.0) 143 (12.7)
 Missing 69 (6.9) 20 (15.0) 89 (7.9)
Multivitamin intake,3 n (%)
 <1 month 661 (66.4) 96 (72.2) 757 (67.1)
 ≥1 month 258 (25.9) 20 (15.0) 278 (24.7)
 Missing 76 (7.6) 17 (12.8) 93 (8.2)
Calcium intake,3 n (%)
 <1 month 821 (82.5) 101 (75.9) 922 (81.7)
 ≥1 month 120 (12.1) 15 (11.3) 135 (12.0)
 Missing 54 (5.4) 17 (12.8) 71 (6.3)
Folic acid intake,3 n (%)
 <1 month 816 (82.0) 117 (88.0) 933 (82.7)
 ≥1 month 135 (13.6) 6 (4.5) 141 (12.5)
 Missing 44 (4.4) 10 (7.5) 54 (4.8)
Cigarette smoking,4 n (%)
 Never smoker 539 (54.2) 84 (63.2) 623 (55.2)
 Former smoker 183 (18.4) 19 (14.3) 202 (17.9)
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No endometrial cancer
N = 995 (88.2%)
Endometrial cancer
N = 133 (11.8%)
Total
N = 1,128
 Current smoker 267 (26.8) 29 (21.8) 296 (26.2)
 Missing 6 (0.6) 1 (0.8) 7 (0.6)
Average number of alcoholic beverages consumed per day, 5 n (%)
 Never 328 (33.0) 54 (40.6) 382 (33.9)
 <1 336 (33.8) 41 (30.8) 377 (33.4)
 ≥1 183 (18.4) 18 (13.5) 201 (17.8)
 Missing 148 (14.9) 20 (15.0) 168 (14.9)
Regular physical activity,6 n (%)
 <3 months 122 (12.3) 19 (14.3) 141 (12.5)
 ≥3 months 873 (87.7) 114 (85.7) 987 (87.5)
1
Age of diagnosis of endometrial cancer for affected women; age of diagnosis of another cancer or hysterectomy or interview for endometrial 
cancer-unaffected women (whichever came first)
2
underweight <18.5 kg/m2, normal (18.5 – 25.0) kg/m2, overweight (25.0 – 29.9 kg/m2), obese (≥30 kg/m2)
3
at least twice a week
4
former smokers defined as carriers who had smoked at least 1 cigarette per day for at least 3 months and had quit more than 2 years before age at 
endometrial cancer or censored age; current smokers defined as carriers who had smoked at least 1 cigarette per day for at least 3 months and 
continued within 2 years of age at endometrial cancer or censored age.
5
4-oz. glasses of wine, or 12-oz. cans or bottles of beer or hard cider, or 1-oz. servings of sake or liquor (spirits)
6
regular physical activity defined as any physical activity for at least 30 minutes per week for at least 3 months
*
carriers who were diagnosed with endometrial cancer or censored more than 2 years before interview had missing for this variable
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Table 1b
Hormonal and reproductive characteristics of women with a germline mutation in a DNA mismatch repair 
gene
No endometrial cancer
N = 995 (88.2%)
Endometrial cancer
N = 133 (11.8%)
Total
N = 1,128
Number of live births, n (%)
 No 238 (23.9) 40 (30.1) 278 (24.7)
 1 113 (11.4) 13 (9.8) 126 (11.2)
 2 289 (29.1) 29 (21.8) 318 (28.2)
 ≥3 325 (32.7) 46 (34.6) 371 (32.9)
 Missing 30 (3.0) 5 (3.8) 35 (3.1)
Age at first live birth
 No live births 238 (23.9) 40 (30.1) 278 (24.7)
 <25 years 431 (43.3) 54(40.6) 485 (43.0)
 ≥25 years 296 (29.8) 34 (25.6) 330 (29.3)
 Missing 30 (3.0) 5 (3.8) 35 (3.1)
Age at last live birth
 No live births 238 (23.9) 40 (30.1) 278 (24.7)
 <30 years 382 (38.4) 34.6 (34.6) 428 (37.9)
 ≥30 years 336 (33.8) 41 (30.8) 377 (33.4)
 Missing 39 (3.9) 6 (4.5) 45 (4.0)
Age at menarche, n (%)
 <13 years 397 (39.9) 57 (42.9) 454 (40.3)
 ≥13 years 569 (57.2) 70 (52.6) 639 (56.7)
 Missing 29 (2.9) 6 (4.5) 35 (3.1)
Menopause status, n (%)
 Pre-menopause 803 (80.7) 90 (67.7) 893 (79.2)
 Natural menopause 113 (11.4) 19 (14.3) 132 (11.7)
 Induced menopause 58 (5.8) 12 (9.0) 70 (6.2)
 Missing 21 (2.1) 12 (9.0) 33 (2.9)
Age at menopause, n (%)
 Pre-menopause 803 (80.7) 90 (67.7) 893 (79.2)
 <50 109 (11.0) 16 (12.0) 125 (11.1)
 ≥50 59 (5.9) 15 (11.3) 74 (6.6)
 Missing 24 (2.4) 12 (9.0) 36 (3.2)
Hormonal contraception use, n (%)
 <1 year 240 (24.1) 57 (42.9) 297 (26.3)
 ≥1 year 733 (73.7) 70 (52.6) 803 (71.2)
 Missing 22 (2.2) 6 (4.5) 28 (2.5)
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No endometrial cancer
N = 995 (88.2%)
Endometrial cancer
N = 133 (11.8%)
Total
N = 1,128
Years of hormonal contraception use, n (%)
 <1 year 240 (24.1) 57 (42.9) 297 (26.3)
 1–4 years 235 (23.6) 32 (24.1) 267 (23.7)
 ≥5 years 460 (46.2) 35 (26.3) 495 (43.9)
 Missing 60 (6.0) 9 (6.8) 69 (6.1)
Postmenopausal hormone use, n (%)
 <1 year 888 (89.3) 112 (84.2) 1000 (88.7)
 ≥1 year, estrogen only 29 (2.9) 3 (2.3) 32 (2.8)
 ≥1 year, estrogen and progestin 37 (3.7) 9 (6.8) 46 (4.1)
 Missing 41 (4.1) 9 (6.8) 50 (4.4)
Years of postmenopausal hormone use, n (%)
 <1 year 888 (89.3) 112 (84.2) 1000 (88.7)
 1–4 years 32 (3.2) 8 (6.0) 40 (3.6)
 ≥5 years 30 (3.0) 4 (3.0) 34 (3.0)
 Missing 45 (4.5) 9 (6.8) 54 (4.8)
Anti-estrogen use, n (%)
 Never 906 (91.1) 115 (86.5) 1,021 (90.5)
 Ever 10 (1.0) 1 (0.8) 11 (1.0)
 Missing 79 (7.9) 17 (12.8) 96 (8.5)
History of gynecologic surgery
 Never 396 (39.8) 118 (88.7) 514 (45.6)
 Hysterectomy (With or without unilateral or bilateral oophorectomy) 229 (23.0) 0 229 (20.3)
 Unilateral or bilateral oophorectomy 7 (0.7) 1 (0.75) 8 (0.7)
 Other gynecological surgery 30 (3.02) 1 (0.75) 31 (2.8)
 History of more than one gynecological surgery 7 (0.7) 5 (3.8) 12 (1.1)
 Unknown 326 (32.8) 8 (6.0) 334 (29.6)
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